Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst ...

Orally administered novel small molecule agonists of the Amylin receptor could overcome these barriers, offering scalable and effective treatments and providing better management for the growing ...

ASC30 oral tablet demonstrated superior PK properties (including a longer t1/2 and higher AUC) to other small molecule oral GLP-1 receptor (GLP-1R) agonists in development, suggesting ASC30 oral ...

Partnership will leverage Iktos's AI-enabled drug discovery platform and Cube Biotech's advanced protein technologies to develop novel agonists of the Amylin Receptor PARIS and MONHEIM, Germany ...

Existing GLP-1 receptor agonist therapies like semaglutide or the peptide Amylin analogue Pramlintide have limited impact due to high costs, accessibility, and undesirable side effects. Orally ...